HIV

Gilead Sciences will present HIV research updates at EACS 2025, focusing on person-centered approaches to eradicate the epidemic. Key highlights include: new safety data for twice-yearly lenacapavir as PrEP, strategies to expand PrEP access in Europe, and five-year BICSTaR results demonstrating Biktarvy’s long-term efficacy. The company will also share data on novel long-acting combination regimens, including once-weekly and twice-yearly treatment options, and participant demographics of ARTISTRY-1 study for complex treatment regimens.